Weng, Yan
Pfizer (United States)
3 papers on CoChatORCID 0000-0001-6404-5759
Most cited papers
- Verified
A long-acting FGF21 molecule, PF-05231023, decreases body weight and improves lipid profile in non-human primates and type 2 diabetic subjects
Talukdar, S., Zhou, Y., Li, D., Rossulek, M., Dong, J., Somayaji, V., Weng, Y., Clark, R., Lanba, A., Owen, B. M., et al. (2016) · Cell Metabolism
Fibroblast Growth Factor ResearchAdipokines, Inflammation, and Metabolic Diseases
Cited by 496
- Verified · note
Liver-specific Deletion of the NADPH-Cytochrome P450 Reductase Gene
Gu, J., Weng, Y., Zhang, Q.-Y., Cui, H., Behr, M., Wu, L., Yang, W., Zhang, L., & Ding, X. (2003) · Journal of Biological Chemistry
Pharmacogenetics and Drug MetabolismDrug-Induced Hepatotoxicity and Protection
Cited by 214
- Verified
Once-weekly administration of a long-acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese people with hypertriglyceridaemia and in non-human primates
Kim, A. M., Somayaji, V. R., Dong, J. Q., Rolph, T. P., Weng, Y., Chabot, J. R., Gropp, K. E., Talukdar, S., & Calle, R. A. (2017) · Diabetes, Obesity and Metabolism
Fibroblast Growth Factor ResearchLipid metabolism and disorders
Cited by 145
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free